All In Biotech

Drug Trial Radar · NCT01708629

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3

Last checked: Nov 20, 2026Latest source record: Jan 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,881 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,881

Actual

Start

Sep 2012

Primary completion

Aug 2014

Study completion Oct 2015

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Oct 17, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis. A second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis. A third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.

Conditions

  • Plaque Psoriasis

Interventions

  • 210 mg brodalumabDrug

    210 mg brodalumab administered SC

  • 140 mg brodalumabDrug

    140 mg brodalumab administered SC

  • ustekinumabDrug

    45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.

  • placeboDrug

    placebo administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Psoriasis Area Severity Index (PASI) 75 at Week 12Time frame: 12 weeks
  2. Percentage of Participants With Static Physician Global Assessment (sPGA) Success Score (Score of 0 or 1) at Week 12 - Comparison to PlaceboTime frame: 12 weeks

Locations

157 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Beverly Hills, California

  • Research Site

    Burbank, California

  • Research Site

    Encino, California

  • Research Site

    Fremont, California

  • Research Site

    Fullerton, California

  • Research Site

    Irvine, California

  • Research Site

    Los Angeles, California

  • Research Site

    Riverside, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    San Francisco, California

  • Research Site

    Denver, Colorado

  • Research Site

    Farmington, Connecticut

  • Research Site

    Trumbull, Connecticut

  • Research Site

    Boca Raton, Florida

  • Research Site

    Coral Gables, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Tamarac, Florida

  • Research Site

    Alpharetta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Macon, Georgia

  • Research Site

    Boise, Idaho

  • Research Site

    Arlington Heights, Illinois

  • Research Site

    Champaign, Illinois

  • Research Site

    Maywood, Illinois

  • Research Site

    Normal, Illinois

  • Research Site

    Wheaton, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    New Albany, Indiana

  • Research Site

    Overland Park, Kansas

  • Research Site

    Overland Park, Kansas

  • Research Site

    Louisville, Kentucky

  • Research Site

    Owensboro, Kentucky

Showing 40 of 157 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.